- Previous Close
38.95 - Open
38.39 - Bid 38.98 x --
- Ask 39.01 x --
- Day's Range
38.70 - 39.67 - 52 Week Range
33.00 - 56.89 - Volume
2,101,400 - Avg. Volume
4,001,744 - Market Cap (intraday)
16.171B - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.25 - Earnings Date --
- Forward Dividend & Yield 0.10 (0.26%)
- Ex-Dividend Date Jul 4, 2024
- 1y Target Est
--
BGI Genomics Co., Ltd. provides genomic sequencing and proteomic services in China and internationally. The company offers solutions to various applications, such as basic research covering human, plant, animal, and microbial species; clinical research in human health; genetic testing and screening; drug discovery and development; and agriculture and biodiversity preservation and sustainability. It also provides DNA, RNA, and customized sequencing solutions; and mass spec services, as well as COVID-19 PCR test kits and COVID lab solutions. In addition, the company offers diagnostics and precision medicines for COVID-19, infectious diseases, and oncology. It serves academic institutions, pharmaceutical companies, health care providers, and other organizations. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.
www.bgi.com3,752
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 300676.SZ
View MorePerformance Overview: 300676.SZ
Trailing total returns as of 1/27/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300676.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300676.SZ
View MoreValuation Measures
Market Cap
16.20B
Enterprise Value
12.31B
Trailing P/E
236.18
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.94
Price/Book (mrq)
1.65
Enterprise Value/Revenue
3.05
Enterprise Value/EBITDA
16.75
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.52%
Return on Assets (ttm)
-0.64%
Return on Equity (ttm)
-1.00%
Revenue (ttm)
4.03B
Net Income Avi to Common (ttm)
-101.62M
Diluted EPS (ttm)
-0.25
Balance Sheet and Cash Flow
Total Cash (mrq)
4.71B
Total Debt/Equity (mrq)
4.02%
Levered Free Cash Flow (ttm)
-707.47M